A Look At Pennant Group (PNTG) Valuation After The Copper Canyon Memory Care Acquisition
Pennant Group (PNTG) just expanded its Arizona footprint by acquiring Copper Canyon Memory Care in Tucson, adding 40 memory care units and putting fresh attention on how the company is positioning its senior housing portfolio.
See our latest analysis for Pennant Group.
Shares have cooled slightly in the past week, with a 7 day share price return down 4.6% after the Copper Canyon deal. However, the 1 month share price return of 15.5% and 3 year total shareholder return near 19x suggest momentum has come from a longer build up of confidence in Pennant’s growth and risk profile.
If this acquisition has you thinking more broadly about healthcare exposure, it could be a good moment to scan the market for other specialised opportunities through the 34 healthcare AI stocks
With revenue at US$1,023.2m, net income of US$30.3m and the stock recently at US$33.92, plus a very large 3 year total shareholder return and an indicated intrinsic discount, is there still an opportunity here, or is the market already pricing in future growth?
Most Popular Narrative: 11.1% Undervalued
At a last close of $33.92 against a most followed fair value estimate of $38.17, the current Pennant Group price sits below that narrative anchor and puts the focus on what is driving the gap.
The accelerating demographic shift of an aging U.S. population is leading to rising demand for home health, hospice, and senior living services, as evidenced by Pennant's strong organic and acquisition-driven volume growth and robust occupancy/pricing trends in senior living, this ongoing demographic wave is likely to continue expanding Pennant's addressable market, supporting durable, long-term revenue growth.
Curious what sits behind that fair value gap? The narrative leans on a mix of revenue expansion, margin lift and a future earnings multiple that has to hold up. The full story connects those moving parts into one cohesive valuation view.
Result: Fair Value of $38.17 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on factors that could shift quickly, including future Medicare reimbursement decisions and how smoothly Pennant integrates and scales newly acquired AMED assets.
Find out about the key risks to this Pennant Group narrative.
Another Angle on Valuation
The DCF pointing to a fair value of $72.46 portrays Pennant Group as heavily undervalued. However, the stock currently trades on a P/E of 38.9x compared with a fair ratio of 27x, the US Healthcare average of 24.6x, and a peer average of 32.8x. This raises the question of whether the market is overpaying today for that long term cash flow story.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals or a clear story taking shape, either way it pays to look at the numbers yourself and decide what really matters. To help frame that view quickly, take a closer look at the 4 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with just one stock, you risk missing opportunities that might fit your goals even better. Use the screener to widen your field of view.
- Spot potential upside by scanning for companies that look attractively priced on fundamentals through the 49 high quality undervalued stocks.
- Prioritise stability by reviewing the 66 resilient stocks with low risk scores when you want stocks with more resilient profiles.
- Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems before others start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com